Nordicblue invests in Gradientech, whose goal is to commercialize a product to quickly determine which antibiotic has the best effect on sepsis (blood poisoning).
Sepsis is a global health problem with 11 million deaths per year. The United States spends $ 24 billion annually on sepsis care and it is the most expensive diagnosis to treat.